Marshall Wace, LLP Royalty Pharma PLC Call Options Transaction History
Marshall Wace, LLP
- $78.4 Billion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RPRX
# of Institutions
444Shares Held
295MCall Options Held
508KPut Options Held
118K-
Morgan Stanley New York, NY39.5MShares$1.27 Billion0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA37.4MShares$1.2 Billion0.02% of portfolio
-
Black Rock Inc. New York, NY23MShares$741 Million0.01% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA17MShares$546 Million0.79% of portfolio
-
Baillie Gifford & CO14.1MShares$455 Million0.28% of portfolio
About Royalty Pharma plc
- Ticker RPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 437,139,008
- Market Cap $14.1B
- Description
- Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic i...